CN1208617A - Nose drops - Google Patents
Nose drops Download PDFInfo
- Publication number
- CN1208617A CN1208617A CN 98118205 CN98118205A CN1208617A CN 1208617 A CN1208617 A CN 1208617A CN 98118205 CN98118205 CN 98118205 CN 98118205 A CN98118205 A CN 98118205A CN 1208617 A CN1208617 A CN 1208617A
- Authority
- CN
- China
- Prior art keywords
- gram
- nasal drop
- present
- quinolones
- ephedrine hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A nose drop prepn. is prepd. by that in every 10 ml. of physiological saline or distilled water, 0.01-0.08 gm. of ephedrine hydrochloride, 0.01-0.3 gm of quinolone and 0.005-0.02 gm of adrenocortical hormone are added. This medicine possesses the functions of antiseptic, diminishing inflammation, anti-allergy, and over 1000 clinic cases show that its total effective rate can be up to more than 95%.
Description
The present invention relates to a kind of rhinitis medication, particularly a kind of nasal drop.
The multiple medicine that is used for the treatment of rhinitis on sale on the market, example hydrochloric acid ephedrine nasal drop, can make vasoconstriction and improve BITONG gas, but can not fit the disease treatment, because concentration reaches 1%, and cause medicamentous rhinitis easily, known to the inventor, also do not have any medicine both can effectively improve BITONG gas at present, have broad-spectrum antibacterial action again, but antiallergic again simultaneously, alleviate the nasal cavity edema, and side effect is few again.
The object of the present invention is to provide and a kind ofly both can effectively improve BITONG gas, have broad-spectrum antibacterial action, antiallergic alleviates edema again, and novel nose drops are controlled in can comprehensively fitting that side effect is little.
The object of the present invention is achieved like this: a kind of nasal drop, contain ephedrine hydrochloride 0.01 to 0.08 gram, quinolones 0.01 to 0.3 gram, adrenocortical hormone medicine 0.005 to 0.02 gram in per 10 ml physiological salines or distilled water.
Quinolones of the present invention furthermore is norfloxacin or ciprofloxacin or ofloxacin.
Adrenal cortex hormones drug of the present invention is a dexamethasone.
The present invention adopts three kinds of compatibility of drugss, thereby adopt the comprehensive suitable way of controlling to reach goal of the invention: owing to adopted more a spot of ephedrine hydrochloride to come vasoconstrictive, both improved BITONG gas thereby can reach, gentle again lasting, be difficult for causing the effect of medicamentous rhinitis; Owing to adopted quinolones broad-spectrum antibacterials such as norfloxacin, can be in the vasoconstrictive effect antibacterial of nasal cavity be played and kill inhibitory action; Adrenal cortex class medicine has antiallergic, alleviates the effect of edema; An amount of organic assembling of composition of the present invention had both been improved nasal airflow, promoted the nasal sinuses drain, alleviated the nasal cavity edema again, antibacterials directly act on effectively kill bacteria of part simultaneously, cure inflammation, and the present invention reaches more than 95% through 1000 many cases clinical observation total effective rates.
By the following examples the present invention is carried out more careful description:
Embodiment 1:
In per 10 ml physiological salines, add ephedrine hydrochloride 0.02 gram, norfloxacin 0.08 gram, dexamethasone 0.01 gram, the dissolving mixing, get final product usage in the common nasal drop bottle of packing into: every day, collunarium was 3 times, and each 3-5 drips.Can be used for having a stuffy nose, flowing after acute and chronic suppuration type maxillary sinusitis, acute and chronic rhinitis, allergic rhinitis, the flu dense tears etc.
Embodiment 2:
In per 10 ml distilled waters, add ephedrine hydrochloride 0.08 gram, ciprofloxacin or ofloxacin 0.1 gram, dexamethasone 0.05 gram.
Claims (3)
1. a nasal drop is characterized in that: contain ephedrine hydrochloride 0.01 to 0.08 gram in per 10 ml physiological salines or distilled water, quinolones 0.01-0.3 gram, adrenocortical hormone medicine 0.005-0.02 gram.
2. nasal drop according to claim 1 is characterized in that described quinolones is the husky star of promise oxygen or ciprofloxacin or ofloxacin.
3. nasal drop according to claim 1 and 2 is characterized in that adrenal cortex hormones drug is a dexamethasone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98118205A CN1075376C (en) | 1998-08-30 | 1998-08-30 | Nose drops |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98118205A CN1075376C (en) | 1998-08-30 | 1998-08-30 | Nose drops |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1208617A true CN1208617A (en) | 1999-02-24 |
| CN1075376C CN1075376C (en) | 2001-11-28 |
Family
ID=5225962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98118205A Expired - Fee Related CN1075376C (en) | 1998-08-30 | 1998-08-30 | Nose drops |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1075376C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168119A (en) * | 2015-10-28 | 2015-12-23 | 周胜光 | Compound nasal inhalation gel preparation for treating rhinitis |
-
1998
- 1998-08-30 CN CN98118205A patent/CN1075376C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168119A (en) * | 2015-10-28 | 2015-12-23 | 周胜光 | Compound nasal inhalation gel preparation for treating rhinitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1075376C (en) | 2001-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019111715A (en) | AMMONIA OXIDIZING MICROORGANISMS FOR APPLICATION AND DELIVERY IN THE INTRANASAL SYSTEM | |
| WO2004105731A8 (en) | Nasal formulations including a topical decongestant and a topical corticosteroid and their use in treatment of obstructive sleep apnea | |
| EP3307293B1 (en) | Formulations for the treatment of disorders of the mouth, throat and respiratory tract | |
| CN103269687A (en) | Bepotastine compositions | |
| AU2013305569A1 (en) | Composition for the treatment of migraine headaches | |
| KR20120046215A (en) | Olopatadine nasal spray regimen for children | |
| KR20110014199A (en) | Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis | |
| Cortés et al. | Executive summary of outpatient parenteral antimicrobial therapy: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases and the Spanish Domiciliary Hospitalisation Society | |
| CN1075376C (en) | Nose drops | |
| WO2006029487A8 (en) | Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis | |
| WO2015122999A1 (en) | Nasal and sinus wash compositions and methods | |
| CN103202881A (en) | External agent composition for treating rash | |
| CN104971349B (en) | A kind of externally used compound preparation | |
| RU2013139704A (en) | USE OF YB-1 PROTEIN AND ITS FRAGMENTS FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| CN1115245A (en) | Anti-cold inhalation and its prepn. method | |
| Yagudina et al. | MARKET REVIEW OF MEDICINES USED IN THE TREATMENT OF HEMOPHILIA UNDER THE FEDERAL PROGRAM" 7 NOSOLOGIES" | |
| CN1222351A (en) | Compound nose drop | |
| CN101396368B (en) | Use of iso-glycyrrhizic acid and salt thereof in treating allergic rhinitis | |
| CN1861088A (en) | Nasal drip liquor for treating rhinitis and nasosinusitis | |
| CN1112188C (en) | Nasal drops | |
| Smith | Managing Allergic Rhinitis. | |
| ANTHRAX | t ANTHRAX (BACILLUS ANTHRACIS) | |
| KR20140132765A (en) | Improved stability of hydromorphone hydrochloride solutions | |
| Moon | Once-Daily Corticosteroids for Mild, Persistent Asthma | |
| WO2022216172A1 (en) | Aqueous aprotinin-containing antiviral pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |